SCHEMBL796285

SCHEMBL796285

Nc1nc(Nc2ccccc2)nc(-c2noc(-c3ccc(COC4CCC4)nc3)n2)n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.36
BLM P54132 1/20 0.36
ALDH1A1 P00352 3/20 0.36
KCNH3 Q9ULD8 1/20 0.35
NPC1 O15118 3/20 0.35
RAB9A P51151 3/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
KDM4E B2RXH2 2/20 0.35
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
USP2 O75604 1/20 0.35
HPGD P15428 1/20 0.35
ALOX15 P16050 1/20 0.35
TSHR P16473 1/20 0.35
HSD17B10 Q99714 1/20 0.35
L3MBTL1 Q9Y468 3/20 0.35
TDP1 Q9NUW8 1/20 0.35
HTT P42858 2/20 0.34
CDK9 P50750 1/20 0.34
IMPDH2 P12268 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL795633 0.86 CNR2 (0.36) MAPTBLMALDH1A1KCNH3NPC1
SCHEMBL10287193 0.82 S1PR1 (0.33) ALDH1A1L3MBTL1HDAC1HDAC6HDAC8
SCHEMBL795333 0.81 PIK3CA (0.41) MAPTALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL15477140 0.79 CHRNA7 (0.38) MAPTBLMALDH1A1NPC1RAB9A
SCHEMBL796276 0.78 NPC1 (0.37) MAPTALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL807919 0.75 MAPT (0.38) MAPTBLMALDH1A1NPC1RAB9A
SCHEMBL795752 0.74 KMT2A (0.43) MAPTBLMALDH1A1NPC1RAB9A
SCHEMBL795379 0.73 ALOX5AP (0.46) MAPTALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL795269 0.73 EPHX2 (0.39) MAPTBLMALDH1A1NPC1RAB9A
SCHEMBL796263 0.73 SMN1; SMN2 (0.42) MAPTALDH1A1NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2616465-B1 TRIAZINE-OXADIAZOLES NOVARTIS AG (CH) 2015-11-04 EP disclosed
US-20150025057-A1 Triazine-oxadiazoles NOVARTIS AG (CH) 2015-01-22 US disclosed
US-8895733-B2 Triazine-oxadiazoles NOVARTIS AG (CH) 2014-11-25 US disclosed
US-20140051676-A1 Triazine-oxadiazoles NOVARTIS AG (CH) 2014-02-20 US disclosed
EP-2616465-A1 TRIAZINE-OXADIAZOLES Novartis AG (CH) 2013-07-24 EP disclosed
WO-2012035023-A1 TRIAZINE-OXADIAZOLES NOVARTIS AG (CH) 2012-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150025057-A1 Triazine-oxadiazoles OPRK1, OPRD1, OPRL1 MAPT 2602/4885BLM 3425/4885ALDH1A1 439/4885
US-20140051676-A1 Triazine-oxadiazoles OPRK1, OPRD1, OPRL1 MAPT 2602/4885BLM 3425/4885ALDH1A1 439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.